3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Lymphoma, Large B-Cell, Diffuse
4
Burkitt Lymphoma
3
Prostatic Neoplasms
2
Lymphoma, Follicular
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Biphenotypic, Acute
1
Endometrial Neoplasms
1
Down Syndrome
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
enzalutamide
21
Magnetic Resonance Spectroscopy
21
apalutamide
17
Androgen Antagonists
14
Specimen Handling
13
Prednisone
13
Abiraterone Acetate
13
abiraterone
9
Docetaxel
9
Radiotherapy
8
Biopsy
8
darolutamide
7
Radiosurgery
7
Pluvicto
7
Nivolumab
7
cabazitaxel
6
Lutetium-177
6
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
6
Lutetium
5
radium Ra 223 dichloride
4
pembrolizumab
4
niraparib
4
gallium 68 PSMA-11
4
cabozantinib
4
bicalutamide
4
atezolizumab
4
Watchful Waiting
4
Surveys and Questionnaires
4
Standard of Care
4
Radiotherapy, Intensity-Modulated
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Prednisolone
×
30 days
×
Clear all
NCT06925737
2026-05-29
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,440 enrolled
NCT06952803
2026-05-19
EvoPAR-PR02
AstraZeneca
Phase 3
Recruiting
700 enrolled